• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Pituitary-independent effect of octreotide on IGF-I generation.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Pokrajac, Ana
    Frystyk, Jan
    Flyvbjerg, Allan
    Trainer, Peter J
    Affiliation
    Department of Endocrinology, Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom.
    Issue Date
    2009
    
    Metadata
    Show full item record
    Abstract
    Background: Somatostatin analogues (SSTAs) are frequently used for medical treatment of acromegaly. The rationale for their use is based on inhibition of pituitary GH secretion; however, there is in vitro evidence that octreotide also acts to inhibit hepatic IGF-I generation. Aim&Design: We studied the pituitary-independent effects of octreotide on IGF-I generation in 11 severely GH deficient humans (age 38, range 23-52; 7 male; BMI 24.7+/-3 kg/m2; peak stimulated GH <3mug/L; 3+/-1 pituitary hormone deficiencies) on a stable dose of GH replacement (0.4+/-0.1 mg) for at least 6 months. Patients were studied before and after 50 mug of subcutaneous octreotide three times a day for 7 days. Results: At study entry, all patients had total IGF-I within age- and gender-related reference range (SDS 0.4+/-1.0). Octreotide treatment resulted in a significant fall in total IGF-I (by 18%, 208+/-89 vs. 173+/-62 mug/L, P=0.04), free IGF-I (by 13%, 0.83+/-0.36 vs. 0.70+/-0.33 mug/L, P=0.01) and IGFBP-3 (6%, 4475+/-745 vs. 4209+/-912 mug/L, P=0.02). Octreotide suppressed fasting insulin from 8.1+/-3.4 to 6.3+/-4.1 mU/L (P=0.01) and was associated with a rise in fasting glucose from 5.2+/-0.9 to 5.8+/-0.9 mmol/L (P<0.01). IGFBP-1 increased by 84% from 42+/-26 to 95+/-52 mug/L (P=0.04). Conclusion: Our study demonstrates that octreotide induces a significant fall in IGF-I in severely GH deficient adults on fixed-dose of GH replacement. This is the evidence for a non-pituitary action of octreotide on the GH/IGF-I axis, most likely by antagonizing the action of GH on hepatic IGF-I generation and indirectly, by suppressing insulin secretion.
    Citation
    Pituitary-independent effect of octreotide on IGF-I generation. 2009: Eur. J. Endocrinol.
    Journal
    European Journal of Endocrinology / European Federation of Endocrine Societies
    URI
    http://hdl.handle.net/10541/52913
    DOI
    10.1530/EJE-08-0822
    PubMed ID
    19141605
    Type
    Article
    Language
    en
    ISSN
    1479-683X
    ae974a485f413a2113503eed53cd6c53
    10.1530/EJE-08-0822
    Scopus Count
    Collections
    All Christie Publications
    Endocrinology

    entitlement

    Related articles

    • Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action.
    • Authors: Ezzat S, Ren SG, Braunstein GD, Melmed S
    • Issue date: 1992 Dec
    • Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement.
    • Authors: Maghnie M, Aimaretti G, Bellone S, Bona G, Bellone J, Baldelli R, de Sanctis C, Gargantini L, Gastaldi R, Ghizzoni L, Secco A, Tinelli C, Ghigo E
    • Issue date: 2005 Apr
    • Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
    • Authors: Hernandez I, Soderlund D, Espinosa-de-los-Monteros AL, Ochoa R, Zarate A, Mercado M
    • Issue date: 1999 Apr
    • Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak.
    • Authors: Feldt-Rasmussen U, Brabant G, Maiter D, Jonsson B, Toogood A, Koltowska-Haggstrom M, Rasmussen AK, Buchfelder M, Saller B, Biller BM
    • Issue date: 2013 May
    • Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
    • Authors: Pekic S, Doknic M, Miljic D, Joksimovic M, Glodic J, Djurovic M, Dieguez C, Casanueva F, Popovic V
    • Issue date: 2006 May
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.